Literature DB >> 11414150

[Incidence and significance of small focal liver lesions in MRI].

B Kreft1, D Pauleit, R Bachmann, R Conrad, A Krämer, H H Schild.   

Abstract

PURPOSE: Analysis of the frequency and significance of small focal liver lesions (< or = 2 cm) detected on MRI in the presence or absence of a history of malignancy.
METHODS: 628 MRI examinations of the liver performed during 1994-1996 were evaluated. The inclusion criterion into the study was the detection of a focal liver lesion with a size < or = 2 cm. The frequency, the size, the diagnostic proof, and the differential diagnosis of the focal liver lesions were analysed with regard to the patients history of a known malignant tumor.
RESULTS: Overall, 179 of the 628 patients (28.5%) had focal liver lesions < or = 2 cm (n = 338). 58.9% of the lesions could be classified based upon follow-up studies by ultrasound, CT or MRI, or by biopsy. The remaining 41.1% of the lesions could not be classified due to the absence of follow-up examinations. 57.3% of all proven lesions were benign and 42.7% were malignant. A history of a malignant tumor was present in 76.7% of all patients with small liver lesions; however, lesions were benign in these patients in 50.6% of the cases. In patients with no known history of a malignancy, 75% of the lesions were benign and 25% were malignant. However, these malignant lesions were in 10/11 cases hepatocellular carcinomas in patients with liver cirrhosis.
CONCLUSION: Even in the presence of a history of a malignant tumor, about 50% of the detected small liver lesions on MRI are benign. In the absence of a tumor history the probability of a small malignant liver lesion is very low, if the patients does not have liver cirrhosis where small hepatocellular carcinomas can be present.

Entities:  

Mesh:

Year:  2001        PMID: 11414150     DOI: 10.1055/s-2001-13340

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  7 in total

Review 1.  Imaging of liver metastases with contrast-specific low-MI real-time ultrasound and SonoVue.

Authors:  T Albrecht; A Oldenburg; J Hohmann; J Skrok; C W Hoffmann; S Schettler; K J Wolf
Journal:  Eur Radiol       Date:  2003-11       Impact factor: 5.315

2.  Intraoperative Contrast-Enhanced Ultrasound in Colorectal Liver Metastasis Surgery Improves the Identification and Characterization of Nodules.

Authors:  Julien Hoareau; Aurélien Venara; Jérôme Lebigot; Jean-Francois Hamel; Emilie Lermite; Francois Xavier Caroli-Bosc; Christophe Aube
Journal:  World J Surg       Date:  2016-01       Impact factor: 3.352

Review 3.  Liver metastases: Contrast-enhanced ultrasound compared with computed tomography and magnetic resonance.

Authors:  Vito Cantisani; Hektor Grazhdani; Cristina Fioravanti; Maria Rosignuolo; Fabrizio Calliada; Daniela Messineo; Maria Giulia Bernieri; Adriano Redler; Carlo Catalano; Ferdinando D'Ambrosio
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Role of contrast enhanced ultrasonography in the assessment of hepatic metastases: A review.

Authors:  Lars Peter Skovgaard Larsen
Journal:  World J Hepatol       Date:  2010-01-27

5.  Prevalence of benign focal liver lesions: ultrasound investigation of 45,319 hospital patients.

Authors:  Tanja Eva-Maria Kaltenbach; Phillip Engler; Wolfgang Kratzer; Suemeyra Oeztuerk; Thomas Seufferlein; Mark Martin Haenle; Tilmann Graeter
Journal:  Abdom Radiol (NY)       Date:  2016-01

Review 6.  A Bibliometric Analysis of the Top 100 Cited Articles on Hepatic Magnetic Resonance Imaging.

Authors:  Waqas Ullah; Hafez Mohammad A Abdullah; Ejaz Ahmad; Mamoon Ur Rashid; Muhammad Bashir; Asad Ur Rahman; Asrar Ahmad; Abu Hurairah
Journal:  Cureus       Date:  2018-06-04

7.  Interpretable Machine Learning for Characterization of Focal Liver Lesions by Contrast-Enhanced Ultrasound.

Authors:  Simona Turco; Thodsawit Tiyarattanachai; Kambez Ebrahimkheil; John Eisenbrey; Aya Kamaya; Massimo Mischi; Andrej Lyshchik; Ahmed El Kaffas
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2022-04-27       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.